Roivant Sciences (ROIV) Stock Overview
A clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ROIV from our risk checks.
ROIV Community Fair Values
Create NarrativeSee what 18 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$10
FV
263.4% overvalued intrinsic discount59
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Roivant Sciences Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$36.34 |
| 52 Week High | US$37.00 |
| 52 Week Low | US$10.90 |
| Beta | 1.13 |
| 1 Month Change | 1.03% |
| 3 Month Change | 23.65% |
| 1 Year Change | 225.34% |
| 3 Year Change | 210.33% |
| 5 Year Change | 265.59% |
| Change since IPO | 249.42% |
Recent News & Updates
Seeking Alpha • Aug 08
Roivant Sciences: The Balance Sheet Has Become A Strategic Weapon
Summary Roivant Sciences is transitioning from an asset-monetization platform to a commercial-stage biopharma, supported by a strong cash position and imminent product launches. ROIV's $4.7 billion pro forma liquidity eliminates near-term dilution risk, enabling commercialization of brepocitinib and continued pipeline investment without adverse equity market reliance. Brepocitinib's FDA Priority Review for dermatomyositis, with potential approval by September 2026, anchors near-term upside, while label expansions target a >280,000 patient opportunity. ROIV's valuation premium reflects pipeline optionality and self-financing strength, but investors must monitor regulatory, capital allocation, and minority interest risks. Read the full article on Seeking Alpha
Narrative Update • Aug 03
ROIV: Late Stage Data Catalysts Will Drive Future Upside Potential
Roivant Sciences' updated analyst price target has shifted to $42, with analysts citing refreshed models after recent earnings, pipeline updates, and IMVT-1402 trial data as key drivers behind the change from the prior $45 view. Analyst Commentary Recent Street research on Roivant Sciences has leaned constructive, with several bullish analysts revising their models after earnings, pipeline updates, and new IMVT-1402 data.Recent updates
Seeking Alpha • Aug 08
Roivant Sciences: The Balance Sheet Has Become A Strategic Weapon
Summary Roivant Sciences is transitioning from an asset-monetization platform to a commercial-stage biopharma, supported by a strong cash position and imminent product launches. ROIV's $4.7 billion pro forma liquidity eliminates near-term dilution risk, enabling commercialization of brepocitinib and continued pipeline investment without adverse equity market reliance. Brepocitinib's FDA Priority Review for dermatomyositis, with potential approval by September 2026, anchors near-term upside, while label expansions target a >280,000 patient opportunity. ROIV's valuation premium reflects pipeline optionality and self-financing strength, but investors must monitor regulatory, capital allocation, and minority interest risks. Read the full article on Seeking AlphaNarrative Update • Aug 03
ROIV: Late Stage Data Catalysts Will Drive Future Upside Potential
Roivant Sciences' updated analyst price target has shifted to $42, with analysts citing refreshed models after recent earnings, pipeline updates, and IMVT-1402 trial data as key drivers behind the change from the prior $45 view. Analyst Commentary Recent Street research on Roivant Sciences has leaned constructive, with several bullish analysts revising their models after earnings, pipeline updates, and new IMVT-1402 data.
Narrative Update • Jul 20
ROIV: Future Drug Launches And Legal Settlement Shape Balanced Risk Profile
Roivant Sciences' analyst price target has moved from $21.00 to $31.50, with analysts pointing to refreshed models after recent earnings, updated pipeline views, and new clinical data as key drivers of their revised assumptions. Analyst Commentary Recent research updates on Roivant Sciences show that many firms are lifting their price targets following earnings and new clinical data, but the tone is not uniformly bullish.
New Narrative • Jul 19
overprices legal wins and pipeline, ignoring fierce anti-FcRn competition, cash redeployment drag, and holding discounts.
The "Roivant Compounding Fantasy" relies on a lazy sum-of-the-parts calculation, treating binary litigation windfalls and a crowded autoimmune pipeline as a bulletproof thesis. Here is why the market is mispricing the structural friction inside Roivant's hub-and-spoke model: 1.Narrative Update • Jul 06
ROIV: Late Stage Pipeline Progress Will Shape Future Upside Potential
Roivant Sciences' analyst fair value estimate has increased from $32.31 to $45.00 as analysts update their models following recent earnings, pipeline data, and revised assumptions on revenue growth, margins, and future P/E levels. Analyst Commentary Recent Street research on Roivant Sciences points to a cluster of higher fair value views, with several bullish analysts revisiting their models after earnings updates and new clinical data.
Narrative Update • Jun 22
ROIV: 2026 Autoimmune Readouts And Regulatory Milestones Will Drive Repricing
Analysts have raised their average price target on Roivant Sciences to $39.04, citing updated models following recent earnings, pipeline data, and revised assumptions regarding the discount rate, profit margin, and forward P/E. Analyst Commentary Recent research updates on Roivant Sciences point to a more constructive stance from several firms, with higher price targets tied to refreshed models following quarterly results, pipeline data and changes to key assumptions such as discount rates, profit margins and forward P/E multiples.Analysis Article • Jun 19
Roivant Sciences (ROIV) Stock Could Be 19.5% Undervalued After Moderna Settlement And Pipeline Progress
Roivant Sciences (ROIV) has drawn fresh attention after announcing a US$2.25b global settlement with Moderna that ends ongoing patent litigation, along with positive IMVT-1402 rheumatoid arthritis data and Breakthrough Therapy Designation for brepocitinib. See our latest analysis for Roivant Sciences. At a share price of US$31.43, Roivant Sciences has seen a 4.63% 7 day share price return and a 13.47% 90 day share price return. Its 1 year total shareholder return of 174.50% and 3 year total...Narrative Update • Jun 06
ROIV: 2026 Autoimmune Readouts And Breakthrough Status Will Drive Repricing
Roivant Sciences' updated analyst price target, which rises from $35.71 to $39.04, reflects analysts' refreshed models following recent earnings, pipeline updates, and data from IMVT-1402 that they view as supportive of the stock's risk and reward profile. Analyst Commentary Street research on Roivant Sciences has recently leaned constructive, with several major firms updating models and adjusting valuation targets after the latest earnings reports and IMVT-1402 data.Narrative Update • May 19
ROIV: Settlement Windfall Will Shift Focus Toward 2026 Clinical Readouts
Analysts have increased their average price target on Roivant Sciences by about $0.04 to $35.71, citing updated models that factor in litigation settlement proceeds, the brepocitinib priority review and a lower assumed discount rate, along with adjusted profit margin and future P/E assumptions. Analyst Commentary Recent research updates on Roivant Sciences show a mix of optimism around litigation proceeds and key pipeline milestones, alongside some caution around how much of this is already reflected in current valuations.Narrative Update • Apr 21
ROIV: Settlement Cash Will Shift Focus Toward 2026 Late Stage Readouts
The updated analyst price target for Roivant Sciences moves from $33.25 to about $35.67, with analysts pointing to revised models that incorporate the Moderna settlement proceeds, a slightly higher assumed discount rate, modest tweaks to long term profit margin expectations, and a higher future P/E multiple. Analyst Commentary Recent research updates focus heavily on the impact of the Moderna settlement, how the proceeds flow through Roivant Sciences' financial model, and what that might mean for valuation versus execution risk.Narrative Update • Apr 05
ROIV: Settlement Cash Will Refocus Story On 2026 Clinical Readouts
Analysts have nudged their average price target for Roivant Sciences to $33, reflecting updated models that factor in the $2.25b litigation settlement with Moderna and the removal of what several firms describe as a major overhang on the story. Analyst Commentary Street research on Roivant Sciences has clustered around two core themes: the impact of the US$2.25b litigation settlement and what that means for valuation, and the shift in focus toward the company’s clinical and execution milestones.Narrative Update • Mar 22
ROIV: Moderna Settlement Cash Sets Up 2026 Clinical Readout Repricing
Narrative Update on Roivant Sciences The analyst price target for Roivant Sciences has been adjusted from $32.27 to $33.25. Analysts cite the Moderna litigation settlement, related $2.25b proceeds, and the removal of a major overhang as key supports for their updated models.Narrative Update • Mar 07
ROIV: Moderna Settlement Clears Path For 2026 Clinical Readout Upside
Analysts have nudged their average price target for Roivant Sciences higher to about $32, supported by updated models that factor in the $2.25b Moderna settlement. They view the resolution of the litigation as lifting a major overhang and refocusing attention on upcoming clinical readouts.Narrative Update • Feb 21
ROIV: 2026 Clinical Readouts Are Expected To Unlock Further Upside
Roivant Sciences' analyst price target has increased from $27.00 to about $31.73 as analysts factor in updated assumptions around revenue growth, margin potential and a lower future P/E based on recent Street research. Analyst Commentary Recent Street research shows a cluster of price target increases for Roivant Sciences, with several firms revisiting their models around revenue potential, profitability and valuation multiples.Narrative Update • Feb 06
ROIV: 2026 Trial Results And IP Litigation Are Expected To Unlock Upside
Narrative Update Analysts have lifted their blended price target on Roivant Sciences by US$3, citing recent Street research that points to ongoing batoclimab Phase 3 trial progress, a clearer 2026 data timeline, and Roivant's position in the royalty dispute backdrop with Moderna. Analyst Commentary Street research on Roivant Sciences is generally constructive, with recent notes focusing on valuation support from batoclimab, the timing of key Phase 3 readouts, and the ongoing royalty dispute backdrop with Moderna.Narrative Update • Jan 22
ROIV: 2026 Trial Readouts And IP Litigation Are Expected To Drive Upside
Narrative Update: Roivant Sciences (ROIV) Analysts have modestly raised their average price target on Roivant Sciences to about $27, citing updated assumptions around batoclimab trial timelines into 2026 and Roivant's role in ongoing Moderna IP litigation as key factors behind the revised outlook. Analyst Commentary Recent research points to a mixed but generally constructive view on Roivant Sciences, with attention on batoclimab timing and the evolving relationship with Moderna as key inputs into valuation and execution risk.Narrative Update • Jan 08
ROIV: 2026 Clinical Readouts And LNP Litigation Are Expected To Drive Upside
Analysts have lifted their price expectations for Roivant Sciences, with the blended fair value estimate moving from US$25.64 to about US$27.00 as they weigh updated Phase 3 timelines, a slightly lower discount rate, and higher assumed future P/E multiples, alongside perceived improvements in counter-party credit quality related to ongoing IP litigation. Analyst Commentary Recent Street research on Roivant Sciences reflects a mix of optimism around the pipeline and valuation support, alongside some caution on execution timing and external legal factors.Narrative Update • Dec 15
ROIV: Late Stage Pipeline And LNP Litigation Will Drive Upside Into 2026
Analysts have nudged their blended fair value estimate for Roivant Sciences higher, lifting the implied price target by about $1 to approximately $25.64. They are factoring in a richer future earnings multiple and growing confidence in the company’s late stage pipeline and ongoing litigation optionality, despite slightly softer margin and growth assumptions.Narrative Update • Nov 30
ROIV: Positive Phase 3 Data Will Drive Shares Into 2026 And Beyond
The analyst price target for Roivant Sciences has increased from approximately $23.27 to $24.55. Analysts cite stronger revenue growth forecasts and recent positive clinical trial updates as factors driving an improved company outlook.Narrative Update • Nov 16
ROIV: Upcoming Data From Phase 3 Trials Will Drive Shares Higher
Analysts have raised their fair value estimate for Roivant Sciences from $20.86 to $23.27 per share. They cite strong Phase 3 trial results, continued clinical progress, and anticipated upcoming catalysts as key factors behind the updated price target.Narrative Update • Oct 31
ROIV: Positive Phase 3 Results And Legal Uncertainty Will Shape Medium-Term Outlook
The analyst price target for Roivant Sciences has been increased by approximately $0.82 to $20.86 per share. Analysts cite strong Phase 3 trial results and a positive outlook for brepocitinib as key drivers of their upward revisions.Narrative Update • Oct 17
Late-stage Trials For Brepocitinib And Batoclimab Will Unlock Potential, But Execution Risks Remain
Analysts have recently increased their price targets for Roivant Sciences. The consensus has moved higher by several dollars per share as positive Phase 3 results for brepocitinib and progress in litigation bolster confidence in the company's outlook.Narrative Update • Oct 03
Late-stage Trials For Brepocitinib And Batoclimab Will Unlock Potential, But Execution Risks Remain
The analyst consensus price target for Roivant Sciences has increased from $18.30 to $20.05. Analysts cite strong Phase 3 dermatomyositis data and anticipated commercial potential as key drivers for the upward revision.Narrative Update • Sep 18
Late-stage Trials For Brepocitinib And Batoclimab Will Unlock Potential, But Execution Risks Remain
Analysts have raised Roivant Sciences’ price target from $17.00 to $18.30, citing bullish expectations for favorable Phase 3 brepocitinib data in dermatomyositis as a key catalyst and reflecting increased optimism around near-term pipeline milestones. Analyst Commentary Bullish analysts expect favorable risk/reward ahead of brepocitinib Phase 3 data in dermatomyositis, with key results anticipated in September.Seeking Alpha • Apr 23
Roivant Sciences: Primed For Growth With A De-Risked Pipeline
Summary Roivant Sciences has strengthened its financial position through strategic divestitures, boasting $5.2 billion in cash and assets, enabling robust funding for its late-stage pipeline. The company's FcRn inhibitor platform, led by IMVT-1402, shows promise in autoimmune diseases, with positive clinical readouts validating its potential. Priovant's brepocitinib, targeting TYK2/JAK1 pathways, is advancing in Phase 3 trials for Dermatomyositis and Non-Infectious Uveitis, addressing significant unmet needs. Current market valuations significantly undervalue Roivant's potential peak sales, suggesting substantial upside potential given its strong cash position and de-risked late-stage pipeline. Read the full article on Seeking AlphaSeeking Alpha • Feb 05
Roivant: Telavant-Like Success Will Be Challenging To Replicate (Rating Downgrade)
Summary Roivant's $7.1B Telavant sale to Roche demonstrated potential, but the company's stock has underperformed, trading flat while S&P 500 gained 19% since April. Brepocitinib shows promise for NIU treatment with Phase 2 success, but faces challenges including safety concerns and competition from Humira in the $1.5B market. Mosliciguat, targeting PH-ILD, could compete with Tyvaso ($433.8M in Q3 sales) through once-daily dosing and novel mechanism, pending Phase 2 results. Company maintains strong financials with $5.4B in cash/investments and 6-year runway at current burn rate of $76M monthly. I am downgrading to "hold" given the unclear path to profitability and challenges in differentiating clinical assets, though I still see value in a barbell portfolio. Read the full article on Seeking Alpha
New Narrative • Jan 26
Late-stage Trials For Brepocitinib And Batoclimab Will Unlock Potential, But Execution Risks Remain
Successful clinical trials and strategic deals may improve revenue and net margins by focusing on high-value areas.Seeking Alpha • Dec 04
Roivant Sciences: A Biotech Growth Play With Major Ambitions
Summary Roivant Sciences leverages its "Vant" model to develop and monetize drug candidates through subsidiaries, ensuring rapid advancement in therapeutic pipelines. Late-stage assets like Brepocitinib, IMVT-1402, and Mosliciguat position Roivant for significant clinical and commercial milestones by 2025. Strategic divestitures, like Dermavant's sale to Organon for $1.2 billion, support shareholder value through share buybacks and bolster financial stability. ROIV has legal risks from ongoing LNP technology lawsuits, but favorable outcomes could significantly improve its long-term outlook as well. Despite its clinical, legal, and cash burn risks, Roivant's diversified late-stage pipeline and robust financials promise significant growth potential. Read the full article on Seeking AlphaShareholder Returns
| ROIV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 9.1% | 6.5% | 2.7% |
| 1Y | 225.3% | 41.0% | 20.9% |
Return vs Industry: ROIV exceeded the US Biotechs industry which returned 41% over the past year.
Return vs Market: ROIV exceeded the US Market which returned 20.9% over the past year.
Price Volatility
| ROIV volatility | |
|---|---|
| ROIV Average Weekly Movement | 6.5% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ROIV has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ROIV's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 721 | Matt Gline | roivant.com |
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves’ disease, difficult-to-treat rheumatoid arthritis, sjögren’s disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company’s lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases.
Roivant Sciences Ltd. Fundamentals Summary
| ROIV fundamental statistics | |
|---|---|
| Market cap | US$26.25b |
| Earnings (TTM) | -US$266.25m |
| Revenue (TTM) | US$7.53m |
3,485x
P/S Ratio-98.6x
P/E RatioIs ROIV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ROIV income statement (TTM) | |
|---|---|
| Revenue | US$7.53m |
| Cost of Revenue | US$731.42m |
| Gross Profit | -US$723.89m |
| Other Expenses | -US$457.64m |
| Earnings | -US$266.25m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.37 |
| Gross Margin | -9,610.89% |
| Net Profit Margin | -3,534.96% |
| Debt/Equity Ratio | 0% |
How did ROIV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/10 07:24 |
| End of Day Share Price | 2026/08/07 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Roivant Sciences Ltd. is covered by 18 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| William Pickering | Bernstein |
| Jeffrey Walch | Bernstein |
| Chi Meng Fong | BofA Global Research |